Cabozantinib (CBZ) is a tyrosine kinase inhibitor (TKI) that downregulates the activation of multiple receptor tyrosine kinases involved in tumor angiogenesis, invasion, and metastasis, including hepatocyte growth factor receptor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2) [5, 6]. Here, MET is linked to neoplasm.